Rhopressa logo
MENU CLOSE

Lower the IOP floor1,2

Rhopressa® achieves an additional 20% IOP reduction regardless of current regimen or baseline pressure1,2

Real-world Multicenter Open-label Study (M.O.S.T.): Change in IOP1

EMGT, a landmark trial, showed that for each 1 mmHg of IOP reduction there is a ~10% reduction in risk of disease progression.3

Study design: Rhopressa® M.O.S.T.

M.O.S.T. (12-week), prospective, multicenter, noncomparative, open-label study of 260 subjects diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT).1

Primary Endpoint1:

  • Percentage change from baseline in mean IOP at Week 12

Secondary Endpoint1:

  • Change from baseline in mean IOP at Week 12
  • Mean IOP at Week 12

The most common ocular adverse event (AE) reported when Rhopressa® was used adjunctively was conjunctival hyperemia (19.9%), resulting in a discontinuation rate of 3.1%. Other common AEs were blurred vision (6.2%), conjunctival hemorrhage (5.0%), and instillation site pain (5.0%).1

Pooled ROCKET Studies

More Rhopressa®-treated patients achieve ≥20% mean diurnal IOP reduction at lower baseline pressures than timolol patients2,4

Percentage of patients achieving ≥20% mean diurnal IOP reduction at Month 32,4

Pooled ROCKET Study Pooled ROCKET Study

Patients with lower baseline pressures may benefit from treatment with Rhopressa®2

Study design: ROCKET 1, 2, and 4:

Double-masked, parallel, noninferiority, Phase 3 studies of once-daily Rhopressa® (netarsudil ophthalmic solution) 0.02% vs twice-daily timolol.5,6

Inclusion criteria5,6:

  • OHT or OAG
  • Unmedicated baseline IOP (post-washout*):
    • ROCKET 1 & 2: >20 to <27 mmHg at 8:00 AM and >17 to <27 mmHg at 10:00 AM and 4:00 PM
    • ROCKET 4: >20 to <30 mmHg at 8:00 AM and >17 to <30 mmHg at 10:00 AM and 4:00 PM

ROCKET 1 (3-month duration)5

Rhopressa® QHS (n=202)

Timolol BID (n=209)

ROCKET 2 (12-month duration)5

Rhopressa® QHS (n=251)

Rhopressa® BID (n=254)

Timolol BID (n=251)

ROCKET 4 (6-month duration)6

Rhopressa® QHS (n=351)

Timolol BID (n=357)

Primary Endpoints5,6:

  • Mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at Week 2, Week 6, and Month 3

The minimum washout period was 4 weeks for patients using prostaglandin analogs or beta-adrenoceptor antagonists prior to study entry, 2 weeks for those using adrenergic agonists, and 5 days for those using muscarinic agonists or carbonic anhydrase inhibitors.

View ROCK Inhibition

ROCK inhibitors are targeting and treating glaucoma differently. See the science behind the results.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

References:

  1. Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021;37(6):1011-1020.
  2. Singh IP, Fechtner RD, Myers JS, et al. Pooled efficacy and safety profile of netarsudil ophthalmic solution 0.02% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2020;29(10):878-884.
  3. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121(1):48-56.
  4. Data on file, Aerie Pharmaceuticals, Inc.
  5. Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
  6. Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104.
X

You are now leaving Rhopressa.com/hcp

Continue

Cancel